<?xml version="1.0" encoding="UTF-8"?>
<p>While the overall prevalence of V106M in subtype C is higher than subtype B (12% 
 <italic>vs.</italic> 0%) in individuals failing NNRTI-based regimens, K103N (29% 
 <italic>vs.</italic> 40%) and Y181C (12% 
 <italic>vs.</italic> 23%) remain important pathways for both subtype C and B, respectively [
 <xref ref-type="bibr" rid="b51-viruses-02-02493">51</xref>]. There appear to be only minor differences in HIV resistance pathways in subtypes A, B, and C with the second generation NNRTI, etravirine [
 <xref ref-type="bibr" rid="b50-viruses-02-02493">50</xref>].
</p>
